Raycheva Ralitsa, Rangelova Vanya, Kevorkyan Ani
Department of Social Medicine and Public Health, Faculty of Public Health, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria.
Department of Epidemiology and Disaster Medicine, Faculty of Public Health, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria.
Healthcare (Basel). 2022 May 25;10(6):980. doi: 10.3390/healthcare10060980.
The concept of improving the quality and safety of healthcare is well known. However, a follow-up question is often asked about whether these improvements are cost-effective. The prevalence of nosocomial infections (NIs) in the neonatal intensive care unit (NICU) is approximately 30% in developing countries. Ventilator-associated pneumonia (VAP) is the second most common NI in the NICU. Reducing the incidence of NIs can offer patients better and safer treatment and at the same time can provide cost savings for hospitals and payers. The aim of the study is to assess the direct costs of VAP in the NICU. This is a prospective study, conducted between January 2017 and June 2018 in the NICU of University Hospital “St. George” Plovdiv, Bulgaria. During this period, 107 neonates were ventilated for more than 48 h and included in the study. The costs for the hospital stay are based on the records from the Accounting Database of the setting. The differences directly attributable to VAP are presented both as an absolute value and percentage, based on the difference between the values of the analyzed variables. There are no statistically significant differences between patients with and without VAP in terms of age, sex, APGAR score, time of admission after birth and survival. We confirmed differences between the median birth weight (U = 924, p = 0.045) and average gestational age (t = 2.14, p = 0.035) of the patients in the two study groups. The median length of stay (patient-days) for patients with VAP is 32 days, compared to 18 days for non-VAP patients (U = 1752, p < 0.001). The attributive hospital stay due to VAP is 14 days. The median hospital costs for patients with VAP are estimated at €3675.77, compared to the lower expenses of €2327.78 for non-VAP patients (U = 1791.5, p < 0.001). The median cost for antibiotic therapy for patients with VAP is €432.79, compared to €351.61 for patients without VAP (U = 1556, p = 0.024). Our analysis confirms the results of other studies that the increased length of hospital stays due to VAP results in an increase in hospital costs. VAP is particularly associated with prematurity, low birth weight and prolonged mechanical ventilation.
提高医疗质量和安全性的理念广为人知。然而,人们常常会追问这些改进是否具有成本效益。在发展中国家,新生儿重症监护病房(NICU)中医院感染(NI)的发生率约为30%。呼吸机相关性肺炎(VAP)是NICU中第二常见的医院感染。降低医院感染的发生率可以为患者提供更好、更安全的治疗,同时也可以为医院和医保支付方节省成本。本研究的目的是评估NICU中VAP的直接成本。这是一项前瞻性研究,于2017年1月至2018年6月在保加利亚普罗夫迪夫“圣乔治”大学医院的NICU进行。在此期间,107名接受机械通气超过48小时的新生儿被纳入研究。住院费用基于该机构会计数据库中的记录。基于分析变量值之间的差异,VAP直接导致的差异以绝对值和百分比形式呈现。在年龄、性别、阿氏评分、出生后入院时间和生存率方面,有VAP和无VAP的患者之间没有统计学上的显著差异。我们证实了两个研究组患者的中位出生体重(U = 924,p = 0.045)和平均胎龄(t = 2.14,p = 0.035)存在差异。有VAP的患者中位住院时间(患者住院天数)为32天,无VAP的患者为18天(U = 1752,p < 0.001)。VAP导致的额外住院时间为14天。有VAP的患者中位住院费用估计为3675.77欧元,无VAP的患者费用较低,为2327.78欧元(U = 1791.5,p < 0.001)。有VAP的患者抗生素治疗中位费用为432.79欧元,无VAP的患者为351.61欧元(U = 1556,p = 0.024)。我们的分析证实了其他研究的结果,即VAP导致的住院时间延长会导致住院成本增加。VAP尤其与早产、低出生体重和机械通气时间延长有关。